Tempus AI, Inc. (NASDAQ:TEM) EVP Sells $5,071,893.52 in Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Erik Phelps sold 61,582 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $82.36, for a total transaction of $5,071,893.52. Following the sale, the executive vice president now owns 153,080 shares in the company, valued at $12,607,668.80. The trade was a 28.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Erik Phelps also recently made the following trade(s):

• On Wednesday, February 5th, Erik Phelps sold 5,934 shares of Tempus AI stock. The stock was sold at an average price of $67.57, for a total transaction of $400,960.38.

Tempus AI Stock Down 10.5 %

Shares of NASDAQ TEM opened at $76.72 on Friday. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $91.45. The company has a 50 day simple moving average of $49.75 and a two-hundred day simple moving average of $51.44. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Institutional Trading of Tempus AI

A number of hedge funds have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI in the 3rd quarter valued at about $30,000. Operose Advisors LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at approximately $25,000. Farther Finance Advisors LLC acquired a new position in shares of Tempus AI during the 4th quarter worth approximately $34,000. Prestige Wealth Management Group LLC raised its stake in shares of Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after buying an additional 965 shares during the period. Finally, NewEdge Advisors LLC purchased a new position in shares of Tempus AI during the 4th quarter valued at approximately $49,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TEM has been the topic of several recent analyst reports. Guggenheim started coverage on Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 target price on the stock. Piper Sandler reiterated a “neutral” rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. TD Cowen restated a “buy” rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research note on Tuesday, January 14th. Finally, Wolfe Research started coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.